You Searched For "Mylan" and got 20 results
Sort By:
USFDA accepts proposed biosimilar application by Mylan, Biocon for review
The application seeks approval of Bevacizumab for the first-line and second-line treatment of pati…
PTI
Mylan, Biocon launch biosimilar of cancer drug Herceptin in US
New Delhi, Dec 2 () Biotechnology major Biocon and drug firm Mylan NV on Monday announced the launc…
PTI
USFDA pulls up Mylan for manufacturing violations at Andhra plant
New Delhi, Nov 18 () American health regulator USFDA has pulled up Mylan Laboratories for violation…
PTI
Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licence
New Delhi, Nov 27 () Biotechnology major Biocon on Wednesday said that US health regulator has appr…
PTI
Mylan is tumbling on reported shortages of its life-saving EpiPens
According to the report, recent actions by US regulators indicate the supply drought could continue…
Daniel Strauss
Biocon, Mylan win patent litigation against Sanofi in US for insulin glargine device
"In October 2017, Sanofi had initiated patent infringement litigation against our NDA in the US Di…
PTI
Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall
New Delhi, Jan 9 () Amid the voluntary recall of Nizatidine API by Mylan, Solara Active Pharma Scie…
PTI
FDA approves Teva's generic EpiPen in blow to Mylan
"Today's approval of the first generic version of the most-widely prescribed epinephrine auto-injec…
Charlotte Hu,Reuters
$11 billion drugmaker Mylan and US drug giant Pfizer are teaming up to reshape Mylan's business. 3 tough questions from Wall Street analyst show the challenging road ahead.
"This is about enhancing every aspect of our organization, starting with the Board of Directors, st…
Emma Court
Mylan skyrockets after securing a merger with Pfizer's off-patent drug unit
The new company will be rebranded and renamed, and Heather Bresch - the chief executive officer of …
Daniel Strauss
Mylan is recalling EpiPens in the US
Mylan was called out in August 2016 for raising the price of the EpiPen to $608.61 from $93.88 over…
Lydia Ramsey
Investigations are piling up at Mylan
But that's not the only legal matter Mylan's facing. The company's also under investigation generic…
Lydia Ramsey
Mylan stock dropped 7% after second quarter sales slumped
Markets Insider
Charlotte Hu
Wall Street analysts are throwing shade at Pfizer's deal with Mylan, saying it will hurt profits through 2020
Several Wall Street analysts noted that the company's decision to merge Upjohn - Pfizer's off-paten…
Ben Winck
Mylan, Dr Reddy's, Aurobindo, and Torrent Pharma can't sell generic Gilenya that is patented by Novartis
A US court has ordered generic drug makers including Mylan, Dr Reddy's Laboratories, Aurobindo Ph…
Not everyone is buying into Mylan's EpiPen price plan
"This step seems like a PR fix more than a real remedy, masking an exorbitant and callous price hik…
Lydia Ramsey
EpiPen-maker Mylan misses on Q3 earnings
Excluding items, such as the $465 million Department of Justice settlement expense, Mylan said it h…
Lydia Ramsey,Reuters
Aurobindo and Intas submit binding offers to buyout Teva UK
Teva is selling its assets after it acquired Allergan Plc's generics business for $40.5-billion in …
The FDA just approved a generic EpiPen, and analysts think it has the potential to upend Mylan's hold on the market
In May 2017, the FDA said that there was a shortage of EpiPens in the US, because of issues with th…